Tags

Type your tag names separated by a space and hit enter

Multidrug-resistant and extended-spectrum beta-lactamase (ESBL)-producing Salmonella enterica (serotypes Typhi and Paratyphi A) from blood isolates in Nepal: surveillance of resistance and a search for newer alternatives.
Int J Infect Dis. 2006 Nov; 10(6):434-8.IJ

Abstract

OBJECTIVES

We evaluated the prevalence of multidrug resistance (MDR) and production of extended spectrum beta-lactamase (ESBL) by Salmonella enterica (serotypes Typhi and Paratyphi A) in a teaching hospital in Nepal. The MDR strains of S. enterica were also tested for susceptibility to newer antibiotics.

METHODS

Blood cultures were obtained from 4105 patients with febrile illnesses. Isolates of S. enterica were serotyped and antibiotic susceptibility testing was carried out using disk diffusion (Kirby-Bauer) and E-tests. ESBL screening and phenotype confirmation were done following National Committee for Clinical Laboratory Standards (NCCLS) recommendations for Escherichia coli.

RESULTS

A total of 541 isolates of S. enterica serotypes Typhi (47%) and Paratyphi A (53%) were grown. Twenty-eight isolates (5%) of S. enterica were resistant to two or more antibiotics (MDR isolates), with a greater prevalence among serotype Paratyphi A (7%). All ESBL producers (three isolates) were serotype Paratyphi A. Most of the MDR S. enterica showed reduced susceptibility to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole, ofloxacin, and ciprofloxacin, and had good susceptibility to extended-spectrum cephalosporins and carbapenems. Among the fluoroquinolones, gatifloxacin demonstrated better in vitro activity compared to levofloxacin, ciprofloxacin, and ofloxacin.

CONCLUSIONS

A greater prevalence of S. enterica serotype Paratyphi A with higher rates of multidrug resistance and ESBL production is concerning for natives as well as travelers in Nepal since the current typhoid vaccines do not provide protection against this serotype.

Authors+Show Affiliations

Department of Microbiology, Tribhuvan University Teaching Hospital, Kathmandu, Nepal.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

16978898

Citation

Pokharel, Bharat M., et al. "Multidrug-resistant and Extended-spectrum Beta-lactamase (ESBL)-producing Salmonella Enterica (serotypes Typhi and Paratyphi A) From Blood Isolates in Nepal: Surveillance of Resistance and a Search for Newer Alternatives." International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases, vol. 10, no. 6, 2006, pp. 434-8.
Pokharel BM, Koirala J, Dahal RK, et al. Multidrug-resistant and extended-spectrum beta-lactamase (ESBL)-producing Salmonella enterica (serotypes Typhi and Paratyphi A) from blood isolates in Nepal: surveillance of resistance and a search for newer alternatives. Int J Infect Dis. 2006;10(6):434-8.
Pokharel, B. M., Koirala, J., Dahal, R. K., Mishra, S. K., Khadga, P. K., & Tuladhar, N. R. (2006). Multidrug-resistant and extended-spectrum beta-lactamase (ESBL)-producing Salmonella enterica (serotypes Typhi and Paratyphi A) from blood isolates in Nepal: surveillance of resistance and a search for newer alternatives. International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases, 10(6), 434-8.
Pokharel BM, et al. Multidrug-resistant and Extended-spectrum Beta-lactamase (ESBL)-producing Salmonella Enterica (serotypes Typhi and Paratyphi A) From Blood Isolates in Nepal: Surveillance of Resistance and a Search for Newer Alternatives. Int J Infect Dis. 2006;10(6):434-8. PubMed PMID: 16978898.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Multidrug-resistant and extended-spectrum beta-lactamase (ESBL)-producing Salmonella enterica (serotypes Typhi and Paratyphi A) from blood isolates in Nepal: surveillance of resistance and a search for newer alternatives. AU - Pokharel,Bharat M, AU - Koirala,Janak, AU - Dahal,Rajan K, AU - Mishra,Shyam K, AU - Khadga,Prem K, AU - Tuladhar,N R, Y1 - 2006/09/15/ PY - 2005/12/05/received PY - 2006/05/12/revised PY - 2006/07/04/accepted PY - 2006/9/19/pubmed PY - 2007/2/8/medline PY - 2006/9/19/entrez SP - 434 EP - 8 JF - International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases JO - Int J Infect Dis VL - 10 IS - 6 N2 - OBJECTIVES: We evaluated the prevalence of multidrug resistance (MDR) and production of extended spectrum beta-lactamase (ESBL) by Salmonella enterica (serotypes Typhi and Paratyphi A) in a teaching hospital in Nepal. The MDR strains of S. enterica were also tested for susceptibility to newer antibiotics. METHODS: Blood cultures were obtained from 4105 patients with febrile illnesses. Isolates of S. enterica were serotyped and antibiotic susceptibility testing was carried out using disk diffusion (Kirby-Bauer) and E-tests. ESBL screening and phenotype confirmation were done following National Committee for Clinical Laboratory Standards (NCCLS) recommendations for Escherichia coli. RESULTS: A total of 541 isolates of S. enterica serotypes Typhi (47%) and Paratyphi A (53%) were grown. Twenty-eight isolates (5%) of S. enterica were resistant to two or more antibiotics (MDR isolates), with a greater prevalence among serotype Paratyphi A (7%). All ESBL producers (three isolates) were serotype Paratyphi A. Most of the MDR S. enterica showed reduced susceptibility to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole, ofloxacin, and ciprofloxacin, and had good susceptibility to extended-spectrum cephalosporins and carbapenems. Among the fluoroquinolones, gatifloxacin demonstrated better in vitro activity compared to levofloxacin, ciprofloxacin, and ofloxacin. CONCLUSIONS: A greater prevalence of S. enterica serotype Paratyphi A with higher rates of multidrug resistance and ESBL production is concerning for natives as well as travelers in Nepal since the current typhoid vaccines do not provide protection against this serotype. SN - 1201-9712 UR - https://www.unboundmedicine.com/medline/citation/16978898/Multidrug_resistant_and_extended_spectrum_beta_lactamase__ESBL__producing_Salmonella_enterica__serotypes_Typhi_and_Paratyphi_A__from_blood_isolates_in_Nepal:_surveillance_of_resistance_and_a_search_for_newer_alternatives_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1201-9712(06)00137-8 DB - PRIME DP - Unbound Medicine ER -